RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Brain enzyme scans, medicines and smoking

This study investigates how Parkinson's medicines and smoking relate to a brain enzyme involved in breaking down chemical signals.

Testing a treatment or activity · Study reference: JPRN-UMIN000049442

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Results reported

Start (reported date)
2022-12-01
Study finished (reported date)
2025-03-31

Planned dates can move. A study finishing does not tell us when a paper will be published.

Read the results reported in the registry

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Ages 50years-old to 90years-old · Ask the team who can join

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: male and female

Inclusion criteria: Parkinson's disease (PD) patients (non-smokers): (1) Informed consent by the participant or by the substitues (native Japanese) (2) Ages: basically 50 to 90 years old (3) Fulfilling the conditions of PD (4) No history of smoking at least 1 year before entry (5) Those who can tolerate PET examination of up to 90 mins Parkinson's disease (PD) patients (non-smokers and plan of MAO-B inhibitor treatment): (1) Informed consent by the participant or by the substitues (native Japanese) (2) Ages: basically 50 to 90 years old (3) Fulfilling the conditions of PD and having the plan of MAO-B inhibitor treatment (should be before starting the treatment) (4) No history of smoking at least 1 year before entry (5) Those who can tolerate PET examination of up to 90 mins Parkinson's disease (PD) patients (smokers): (1) Informed consent by the participant or by the substitues (native Japanese) (2) Ages: basically 50 to 90 years old (3) Fulfilling the conditions of PD (4) Habitual smokers or having history of smoking at least 7 days before the entry (5) Those who can tolerate PET examination of up to 90 mins Healthy controls (non-smokers): (1) Informed consent by the participant or by the substitues (native Japanese) (2) Ages: basically 50 to 90 years old (3) Habitual smoking or history of smoking within 7 days of PET examination (4) Those who can tolerate PET examination of up to 90 mins Healthy controls (non-smokers): (1) Informed consent by the participant or by the substitues (native Japanese) (2) Ages: basically 50 to 90 years old (3) Habitual smoking or history of smoking within 7 days of PET examination (4) Those who can tolerate PET examination of up to 90 mins Healthy controls (smokers): (1) Informed consent by the participant or by the substitues (native Japanese) (2) Ages: basically 50 to 90 years old (3) Habitual smoking or history of smoking within 7 days of PET examination (4) Those who can tolerate PET examination of up to 90 mins Exclusion criteria: (1) Administration of irreversible MAO-B inhibitors, Habitual smoking (within 1 year of entry) (2) Being in the period of pregnancy, possible pregnancy, breast feeding, within 28 days after child birth (3) Severe allergic reactions to drugs and foods (4) Psychiatric disorders, which may make the participation to this study difficult (5) Taboo conditions for MRI examinations (cardiac pacemaker, intracorpoporial metals, etc. to be checked with questionnaire in advance) (6) Systemic circulatory and metabolic disorders as well as organ dysfuctions, such as diabetes melitus, hypertension, endocrinolog ical disorders, congestive heart failure, angina petoris, severe renal dysfunctions with Ccr<30mL/min or under plasmapheresis) (7) Past history of malignant diseases within 1 year of entry (8) Any sociomedial conditions, which may make the participation to this study difficult
Full study name & original research details

Official study title

Study on monoamine oxidase B (MAO-B) distribution differences associated with MAO-B inhibitors and smoking in Parkinson's disease: SMBT-1 PET study - MAO-B research in Parkinson's disease: SMBT-1 PET study

Short title used by the registry

Study on monoamine oxidase B (MAO-B) distribution differences associated with MAO-B inhibitors and smoking in Parkinson's disease

Original description

Intervention: To conduct PET examinations using the following tracers: 18F-SMBT-1 To examine the effects of the following tracers on 18F-SMBT-1 PET: rasagiline To examine the effects of the following tracers on 18F-SMBT-1 PET: selegiline To examine the effects of the following tracers on 18F-SMBT-1 PET: safinamide Effects of habitual smoking Primary outcome: SUV ratio (SUVR)

Conditions reported: Parkinson's disease (PD)

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Interventional
Interventions
To conduct PET examinations using the following tracers: 18F-SMBT-1 To examine the effects of the following tracers on 18F-SMBT-1 PET: rasagiline To examine the effects of the following tracers on 18F-SMBT-1 PET: selegiline To examine the effects of the following tracers on 18F-SMBT-1 PET: safinamide Effects of habitual smoking
Phases
Not selected
Sponsor
Cyclotron and Radioisotope Center, Tohoku University
Start date reported by registry
2022-12-01 (reported)

Registry updated: Not reported · Status last verified by the registry submitter: Not reported

Registry records retrieved 2026-10-11 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Kotaro Hiraoka · +81227957802 · khiraoka@cyric.tohoku.ac.jp

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Facility not reported

Japan

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.